. School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 201100, China . School of Medicine, Shanghai Jiao Tong University, Shanghai 201100, China . Shanghai Mental Health Center, Shanghai 200030, China
Just Accepted Date: 14 September 2024Issue Date: 28 October 2024
Cite this article:
Weihao LI,Zhe LIU,Yihang BAO, et al. Mutation-drug sensitivity data resource (MDSDR):a comprehensive resource for studying and addressing drug resistance[J]. Front. Comput. Sci.,
2025, 19(6): 196913.
Fig.1 Effect of mutations on drug response: (a) Drug binds to its target protein; (b) mutation in target protein prevents binding, causing resistance; (c) mutation in enzyme that aids binding also prevents the drug from binding, causing resistance
Fig.2 Overview of MDSDR’s architecture
1
T, Haider V, Pandey N, Banjare P N, Gupta V Soni . Drug resistance in cancer: mechanisms and tackling strategies. Pharmacological Reports, 2020, 72( 5): 1125–1151
2
G, Housman S, Byler S, Heerboth K, Lapinska M, Longacre N, Snyder S Sarkar . Drug resistance in cancer: an overview. Cancers, 2014, 6( 3): 1769–1792
3
F X, Wu F, Wang J F, Yang W, Jiang M Y, Wang C Y, Jia G F, Hao G F Yang . AIMMS suite: a Web server dedicated for prediction of drug resistance on protein mutation. Briefings in Bioinformatics, 2020, 21( 1): 318–328
4
M, Griffith N C, Spies K, Krysiak J F, Mcmichael A C, Coffman A M, Danos B J, Ainscough C A, Ramirez D T, Rieke L, Kujan E K, Barnell A H, Wagner Z L, Skidmore A, Wollam C J, Liu M R, Jones R L, Bilski R, Lesurf Y Y, Feng N M, Shah M, Bonakdar L, Trani M, Matlock A, Ramu K M, Campbell G C, Spies A P, Graubert K, Gangavarapu J M, Eldred D E, Larson J R, Walker B M, Good C, Wu A I, Su R, Dienstmann A A, Margolin D, Tamborero N, Lopez-Bigas S J M, Jones R, Bose D H, Spencer L D, Wartman R K, Wilson E R, Mardis O L Griffith . CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics, 2017, 49( 2): 170–174
5
M, Whirl-Carrillo R, Huddart L, Gong K, Sangkuhl C F, Thorn R, Whaley T E Klein . An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 2021, 110( 3): 563–572
6
Y, Shen Y, Zhang W, Xue Z Yue . dbMCS: a database for exploring the mutation markers of anti-cancer drug sensitivity. IEEE Journal of Biomedical and Health Informatics, 2021, 25( 11): 4229–4237
7
Behan F M, Iorio F, Picco G, et al. Prioritization of Cancer therapeutic targets using CRISPR-Cas9 screens. Nature, 2019, 568: 511–516
8
W, Yang J, Soares P, Greninger E J, Edelman H, Lightfoot S, Forbes N, Bindal D, Beare J A, Smith I R, Thompson S, Ramaswamy P A, Futreal D A, Haber M R, Stratton C, Benes U, Mcdermott M J Garnett . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 2012, 41( D1): D955–D961
9
X, Liu T, Shen B H M, Mooers F, Hilberg J Wu . Drug resistance profiles of mutations in the RET kinase domain. British Journal of Pharmacology, 2018, 175( 17): 3504–3515
10
K, Hauser C, Negron S K, Albanese S, Ray T, Steinbrecher R, Abel J D, Chodera L Wang . Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. Communications Biology, 2018, 1: 70
11
Z, Yang Z, Ye J, Qiu R, Feng D, Li C, Hsieh J, Allcock S Zhang . A mutation-induced drug resistance database (MdrDB). Communications Chemistry, 2023, 6( 1): 123
12
Consortium UniProt . UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Research, 2023, 51( D1): D523–D531
